Bacillus anthracis Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges in developing rapid diagnostics for biodefense countermeasures, or struggling to obtain highly potent neutralizing antibodies against Anthrax toxin components? Our B. anthracis Specific Neutra™ Antibody Products help you accelerate critical research, obtain high-quality recombinant proteins, and develop highly specific therapeutic candidates through innovative protein engineering techniques and robust validation platforms.
Contact our team to get an inquiry now!
Introduction of B. anthracis
Bacillus anthracis is a Gram-positive, spore-forming, rod-shaped bacterium renowned as the causative agent of anthrax, a severe disease impacting both animals and humans. The organism's persistence in the environment is attributed to its robust spore form, which can remain dormant for decades and represents the primary infective particle upon inhalation, ingestion, or cutaneous entry.
The lethality of B. anthracis is predominantly mediated by two plasmid-encoded virulence factors: the poly-γ-D-glutamic acid capsule (which provides immune evasion) and the tripartite anthrax toxin. This toxin is comprised of three individual, non-toxic proteins that act synergistically to cause systemic damage: Protective Antigen (PA), Lethal Factor (LF), and Edema Factor (EF). PA, an 83 kDa protein, is the central component. It first binds to host cell receptors (e.g., TEM8 and CMG2). Following receptor binding, PA is proteolytically cleaved into a PA63 fragment, which then self-assembles into a heptameric or octameric pre-pore structure on the cell surface. This assembly is crucial as it creates the conduit necessary for translocating the enzymatic components, LF and EF, into the host cell cytosol, ultimately leading to macrophage lysis, cell death, and edema. This mechanism makes PA the critical point of vulnerability for therapeutic intervention.
Fig.1 Molecular mechanisms of B anthracis.1
Antibodies Against B. anthracis
Antibodies represent a powerful and highly specific countermeasure strategy against B. anthracis, with the Protective Antigen (PA) being the most validated and crucial target for both detection and neutralization. High-affinity antibodies targeting PA are essential because they prevent the initial binding and subsequent oligomerization steps, effectively disarming the toxin before cellular damage can occur.
The Creative Biolabs Neutra™ Antibody Products are designed to deliver superior performance in various immunological and functional assays. These antibodies are indispensable for:
- Toxin Neutralization Assays: Quantifying the ability of compounds or serum to block PA-mediated intoxication in vitro, a critical step in antitoxin drug development.
- Antigen Detection: Utilizing platforms such as Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blotting (WB) for the rapid and accurate detection of PA in environmental samples or clinical specimens.
- Pathogenesis Research: Enabling Immunofluorescence (IF) and Flow Cytometry studies to track PA binding and internalization mechanisms in different cell lines.
- Vaccine Efficacy Assessment: Serving as reliable reagents to measure the immune response generated by vaccine candidates in preclinical models.
By focusing on this well-defined and essential target, our antibodies provide researchers with the tools needed to develop highly effective diagnostic and therapeutic solutions.
Why Choose Us?
Creative Biolabs provides specialty biological reagents with over years of experience. Our commitment to deep scientific expertise and quality ensures our B. anthracis Specific Neutra™ Antibody Products provide a competitive edge for your mission-critical research.
Key Advantages of Choosing Creative Biolabs:
- Superior Affinity and Specificity: Rigorous, multi-stage validation ensures specific PA epitope binding and minimal cross-reactivity, guaranteeing reliable results.
- Validated Neutralization Efficacy: Every batch is functionally validated in standard in vitro toxin neutralization assays, confirming biological activity for therapeutic development (Published Data).
- Consistent Manufacturing: Advanced protein engineering and quality control ensure exceptional lot-to-lot consistency, vital for long-term research and preclinical studies.
- Comprehensive Application Support: Our antibodies are confirmed for use across a broad spectrum of applications, including ELISA, WB, and IF, ensuring experimental versatility.
FAQs
Q: What is the most critical target on the B. anthracis bacterium for developing effective neutralizing antibodies?
A: The Protective Antigen (PA) component of the anthrax toxin is the most critical target. Antibodies directed against PA block the toxin's binding, pore formation, and the subsequent entry of Lethal Factor (LF) and Edema Factor (EF). Neutralizing PA effectively disarms the entire toxin complex.
Q: Are these antibodies validated for use in functional neutralization assays, or are they only suitable for simple detection?
A: These tools must be validated for functional use. They are tested in cell-based neutralization assays to confirm their capacity to inhibit the anthrax toxin's cytotoxic effects. This validation ensures their relevance for preclinical antitoxin and vaccine development, going beyond simple binding detection.
Q: How can researchers minimize non-specific background signals when using high-affinity antibodies in complex biological samples?
A: Minimizing background is crucial for clean data. Recommended precautions include optimizing antibody concentration, utilizing appropriate blocking buffers, and ensuring thorough washing steps. Employing a highly purified, affinity-matched secondary antibody and a high signal-to-noise ratio detection method also significantly helps reduce interference.
Q: What are the key advantages of using antibody-based immunoassays over conventional culture methods for rapid screening of B. anthracis antigens?
A: Immunoassays offer substantial advantages in speed, throughput, and sensitivity. Unlike time-consuming culture methods, immunoassays deliver results in hours. They are highly scalable for high-throughput screening and can detect specific protein antigens efficiently, even in non-viable or low-concentration samples.
Q: Can these reagents be used to differentiate between the anthrax toxin components (PA, LF, and EF) or are they primarily targeted at the whole organism?
A: These reagents are typically developed with exquisite specificity to individual toxin components (e.g., anti-PA or anti-LF). This is essential for detailed mechanistic studies of each toxin part and for developing specific antitoxin agents, differentiating them from general tools that target somatic spore antigens.
Access the Creative Biolabs Edge – Request Your Quote Now
REFERENCE
- Ogunleye, Seto C., et al. "Anthrax outbreak: exploring its biological agents and public health implications." Frontiers in Tropical Diseases 4 (2024): 1297896. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fitd.2023.1297896
